446 related articles for article (PubMed ID: 33431660)
41. Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective.
Chen YC; Shi W; Shi JJ; Lu JJ
J Cancer Res Clin Oncol; 2022 Jan; 148(1):1-14. PubMed ID: 34609596
[TBL] [Abstract][Full Text] [Related]
42. A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology.
Burgess TL; Amason JD; Rubin JS; Duveau DY; Lamy L; Roberts DD; Farrell CL; Inglese J; Thomas CJ; Miller TW
PLoS One; 2020; 15(4):e0226661. PubMed ID: 32240171
[TBL] [Abstract][Full Text] [Related]
43. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
Wang X; Wang Y; Hu J; Xu H
Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
[TBL] [Abstract][Full Text] [Related]
44. Novel fully human anti-CD47 antibodies stimulate phagocytosis and promote elimination of AML cells.
Wang C; Sun C; Li M; Xia B; Wang Y; Zhang L; Zhang Y; Wang J; Sun F; Lu S; Zhu J; Huang J; Zhang Y
J Cell Physiol; 2021 Jun; 236(6):4470-4481. PubMed ID: 33206395
[TBL] [Abstract][Full Text] [Related]
45. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.
Piccione EC; Juarez S; Tseng S; Liu J; Stafford M; Narayanan C; Wang L; Weiskopf K; Majeti R
Clin Cancer Res; 2016 Oct; 22(20):5109-5119. PubMed ID: 27126995
[TBL] [Abstract][Full Text] [Related]
46. Nanocages displaying SIRP gamma clusters combined with prophagocytic stimulus of phagocytes potentiate anti-tumor immunity.
Choi Y; Nam GH; Kim GB; Kim S; Kim YK; Kim SA; Kim HJ; Lee EJ; Kim IS
Cancer Gene Ther; 2021 Sep; 28(9):960-970. PubMed ID: 34349240
[TBL] [Abstract][Full Text] [Related]
47. Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPα Interaction as a Potential Cancer Immunotherapy.
Hazama D; Yin Y; Murata Y; Matsuda M; Okamoto T; Tanaka D; Terasaka N; Zhao J; Sakamoto M; Kakuchi Y; Saito Y; Kotani T; Nishimura Y; Nakagawa A; Suga H; Matozaki T
Cell Chem Biol; 2020 Sep; 27(9):1181-1191.e7. PubMed ID: 32640189
[TBL] [Abstract][Full Text] [Related]
48. CD47: role in the immune system and application to cancer therapy.
Hayat SMG; Bianconi V; Pirro M; Jaafari MR; Hatamipour M; Sahebkar A
Cell Oncol (Dordr); 2020 Feb; 43(1):19-30. PubMed ID: 31485984
[TBL] [Abstract][Full Text] [Related]
49. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy.
Jia X; Yan B; Tian X; Liu Q; Jin J; Shi J; Hou Y
Int J Biol Sci; 2021; 17(13):3281-3287. PubMed ID: 34512146
[TBL] [Abstract][Full Text] [Related]
50. Selection and Characterization of FD164, a High-Affinity Signal Regulatory Protein
Wang Z; Hu N; Li X; Wang H; Ren C; Qiao C; Chen G; Wang J; Zhou L; Wu J; Zhang D; Feng J; Shen B; Peng H; Luo L
Mol Pharmacol; 2021 Sep; 100(3):193-202. PubMed ID: 34315811
[TBL] [Abstract][Full Text] [Related]
51. Biomimetic Nano-Degrader Based CD47-SIRPα Immune Checkpoint Inhibition Promotes Macrophage Efferocytosis for Cardiac Repair.
Gao J; Pang Z; Wang Q; Tan Y; Li Q; Tan H; Chen J; Yakufu W; Wang Z; Yang H; Zhang J; Sun D; Weng X; Wang Q; Qian J; Song Y; Huang Z; Ge J
Adv Sci (Weinh); 2024 Jun; 11(24):e2306388. PubMed ID: 38477522
[TBL] [Abstract][Full Text] [Related]
52. Anticancer efficacy of monotherapy with antibodies to SIRPα/SIRPβ1 mediated by induction of antitumorigenic macrophages.
Sakamoto M; Murata Y; Tanaka D; Kakuchi Y; Okamoto T; Hazama D; Saito Y; Kotani T; Ohnishi H; Miyasaka M; Fujisawa M; Matozaki T
Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34949714
[TBL] [Abstract][Full Text] [Related]
53. RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages.
Cabrales P
Transl Oncol; 2019 Apr; 12(4):626-632. PubMed ID: 30738349
[TBL] [Abstract][Full Text] [Related]
54. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
55. Just eat it: A review of CD47 and SIRP-α antagonism.
Oronsky B; Carter C; Reid T; Brinkhaus F; Knox SJ
Semin Oncol; 2020; 47(2-3):117-124. PubMed ID: 32517874
[TBL] [Abstract][Full Text] [Related]
56. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile.
Kauder SE; Kuo TC; Harrabi O; Chen A; Sangalang E; Doyle L; Rocha SS; Bollini S; Han B; Sim J; Pons J; Wan HI
PLoS One; 2018; 13(8):e0201832. PubMed ID: 30133535
[TBL] [Abstract][Full Text] [Related]
57. Combining SiRPα decoy-coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells.
Stefanidis E; Semilietof A; Pujol J; Seijo B; Scholten K; Zoete V; Michielin O; Sandaltzopoulos R; Coukos G; Irving M
J Clin Invest; 2024 Apr; 134(11):. PubMed ID: 38828721
[TBL] [Abstract][Full Text] [Related]
58. CD47-SIRPα Controls ADCC Killing of Primary T Cells by PMN Through a Combination of Trogocytosis and NADPH Oxidase Activation.
Gondois-Rey F; Miller T; Laletin V; Morelli X; Collette Y; Nunès J; Olive D
Front Immunol; 2022; 13():899068. PubMed ID: 35795660
[TBL] [Abstract][Full Text] [Related]
59. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway.
Matozaki T; Murata Y; Okazawa H; Ohnishi H
Trends Cell Biol; 2009 Feb; 19(2):72-80. PubMed ID: 19144521
[TBL] [Abstract][Full Text] [Related]
60. A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities.
Wu F; Qiu Y; Xu Y
Cancer Immunol Immunother; 2020 Dec; 69(12):2561-2569. PubMed ID: 32583154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]